Literature DB >> 8878430

Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission.

J Townsley-Fuchs1, L Kam, R Fairhurst, S J Gange, L Goodglick, J V Giorgi, N Sidell, R Detels, J Braun.   

Abstract

HIV-1 gp120 is an immunoglobulin superantigen which can bind to preimmune serum Ig. We hypothesize that levels of such preimmune antibodies vary in the population and might affect host resistance or susceptibility to viral transmission. This study tests two predictions: (a) levels of preimmune anti-gpl20 Igs are a polymorphic trait; and, (b) these levels are correlated with resistance or susceptibility to HIV-1 transmission. The first prediction was confirmed in a longitudinal study of a low-risk seronegative population. In this group, levels of both endogenous anti-gpl20 IgM and IgG varied widely, but were characteristic and stable for each individual. The second prediction was addressed in a study of participants of the Multicenter AIDS Cohort Study, in which men "susceptible" and "resistant" to HIV infection were identified based on numbers of sexual partners and eventual seroconversion. Specimens consisted of archival sera obtained > 2 yr before seroconversion. Men in the susceptible population (low-risk seroconverters) were distinguished by low levels of anti-gpl20 IgG. We conclude that the level of preimmune anti-gpl20 IgG is a polymorphic population trait, and low levels are a potentially specific and significant factor in homosexual transmission of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878430      PMCID: PMC507618          DOI: 10.1172/JCI118979

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

Review 1.  B-cell superantigens: implications for selection of the human antibody repertoire.

Authors:  M Zouali
Journal:  Immunol Today       Date:  1995-08

2.  Negative selection of multireactive B cell clones in normal adult mice.

Authors:  A Grandien; R Fucs; A Nobrega; J Andersson; A Coutinho
Journal:  Eur J Immunol       Date:  1994-06       Impact factor: 5.532

Review 3.  Revenge of the microbes. Superantigens of the T and B cell lineage.

Authors:  L Goodglick; J Braun
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

4.  High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG.

Authors:  P A Kozlowski; K P Black; L Shen; S Jackson
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

5.  Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup.

Authors:  E H Sasso; G J Silverman; M Mannik
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

6.  Increasing HIV-1 seroprevalence associated with genital ulcer disease, New York City, 1990-1992.

Authors:  L V Torian; I B Weisfuse; H A Makki; D A Benson; L M DiCamillo; F E Toribio
Journal:  AIDS       Date:  1995-02       Impact factor: 4.177

Review 7.  Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?

Authors:  D S Burke
Journal:  Perspect Biol Med       Date:  1992       Impact factor: 1.416

8.  Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacs.

Authors:  M M Lederman; J B Jackson; B L Kroner; G C White; M E Eyster; L M Aledort; M W Hilgartner; C M Kessler; A R Cohen; K P Kiger
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

9.  Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course.

Authors:  T H Lee; H W Sheppard; M Reis; D Dondero; D Osmond; M P Busch
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-04

10.  Molecular analysis of original antigenic sin. I. Clonal selection, somatic mutation, and isotype switching during a memory B cell response.

Authors:  S Fish; E Zenowich; M Fleming; T Manser
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

View more
  11 in total

1.  A covalent HIV vaccine: is there hope for the future?

Authors:  Sudhir Paul; Stephanie A Planque; Yasuhiro Nishiyama; Carl V Hanson
Journal:  Future Virol       Date:  2009       Impact factor: 1.831

Review 2.  Antibodies as defensive enzymes.

Authors:  Sudhir Paul; Yasuhiro Nishiyama; Stephanie Planque; Sangeeta Karle; Hiroaki Taguchi; Carl Hanson; Marc E Weksler
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

3.  Molecular determinants of the human antibody response to HIV-1: implications for disease control.

Authors:  M Viau; M Zouali
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

4.  Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination.

Authors:  Hok Hei Tam; Mariane B Melo; Myungsun Kang; Jeisa M Pelet; Vera M Ruda; Maria H Foley; Joyce K Hu; Sudha Kumari; Jordan Crampton; Alexis D Baldeon; Rogier W Sanders; John P Moore; Shane Crotty; Robert Langer; Daniel G Anderson; Arup K Chakraborty; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-04       Impact factor: 11.205

5.  Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection.

Authors:  Stephanie Planque; Maria Salas; Yukie Mitsuda; Marcin Sienczyk; Miguel A Escobar; Jason P Mooney; Mary-Kate Morris; Yasuhiro Nishiyama; Dipanjan Ghosh; Amit Kumar; Feng Gao; Carl V Hanson; Sudhir Paul
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177

Review 6.  Back to the future: covalent epitope-based HIV vaccine development.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama; Miguel Escobar; Carl Hanson
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

Review 7.  The search for protection against HIV infection.

Authors:  Roger Detels
Journal:  Ann Epidemiol       Date:  2009-04       Impact factor: 3.797

8.  Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.

Authors:  Stephanie A Planque; Yukie Mitsuda; Yasuhiro Nishiyama; Sangeeta Karle; Stephane Boivin; Maria Salas; Mary-Kate Morris; Mariko Hara; Guangling Liao; Richard J Massey; Carl V Hanson; Sudhir Paul
Journal:  J Immunol       Date:  2012-10-22       Impact factor: 5.422

Review 9.  Catalytic antibodies to HIV: physiological role and potential clinical utility.

Authors:  Stephanie Planque; Yasuhiro Nishiyama; Hiroaki Taguchi; Maria Salas; Carl Hanson; Sudhir Paul
Journal:  Autoimmun Rev       Date:  2008-04-29       Impact factor: 9.754

10.  CD4 binding determinant mimicry for HIV vaccine design.

Authors:  Yasuhiro Nishiyama; Stephanie Planque; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  Front Immunol       Date:  2012-12-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.